PPHF 2016: PPHF Epidemiology and Laboratory Capacity Program – US Platform to Measure Influenza Vaccine Effectiveness against Laboratory-confirmed Influenza-associated Hospitalizations – financed in part by 2016 Prevention and Public Heal | RFA IP 15 00202CONTPPHF16

Opportunity Information: Apply for RFA IP 15 00202CONTPPHF16

This grant opportunity, titled "PPHF 2016: PPHF Epidemiology and Laboratory Capacity (ELC) Program - US Platform to Measure Influenza Vaccine Effectiveness against Laboratory-confirmed Influenza-associated Hospitalizations," is a continuation cooperative agreement offered by the Centers for Disease Control and Prevention (CDC) under CFDA 93.733. Its main purpose is to support an ongoing national platform that can produce reliable, year-to-year estimates of how well seasonal influenza vaccines work at preventing serious flu outcomes, specifically laboratory-confirmed influenza-associated hospitalizations. Because influenza viruses evolve continually and vaccine formulations are updated each season, the program emphasizes the public health need for consistent annual vaccine effectiveness estimates to help interpret the value of vaccination programs and guide decisions in prevention policy and clinical practice.

The opportunity is framed around influenza as a major and recurring driver of illness, deaths, and healthcare system strain across all age groups in the United States. The core idea is that measuring vaccine effectiveness is not a one-time evaluation; it has to be repeated every season since circulating strains, population immunity, and vaccine match can change. By focusing on hospitalizations with laboratory confirmation, the platform is aimed at measuring protection against more severe disease, using standardized surveillance and testing approaches that can support credible comparisons across sites and seasons.

This funding announcement is identified as a continuation (Funding Opportunity Number RFA IP 15 00202CONTPPHF16), meaning it is intended to extend or sustain existing work rather than start an entirely new initiative from scratch. The funding instrument is a cooperative agreement, which typically indicates substantial involvement by CDC in the project, such as collaboration on protocols, data standards, analytic methods, and reporting expectations. The anticipated number of awards is five, and the published award ceiling is listed as 0, which commonly indicates that a single fixed maximum was not specified in the public summary and that award amounts may depend on available funds, approved budgets, and negotiated scopes of work. The original closing date for the opportunity was June 24, 2016, and it was posted on May 24, 2016. The title also notes that the work is financed in part by the 2016 Prevention and Public Health Fund (PPHF), signaling that PPHF dollars are a component of the funding source supporting the activity.

Eligibility is broad and includes many types of public and private entities that could contribute to influenza surveillance, epidemiology, and laboratory-supported evaluation. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofit organizations with 501(c)(3) status (excluding institutions of higher education in that category); private institutions of higher education; for-profit organizations (other than small businesses); and small businesses. In practical terms, that range reflects the fact that measuring vaccine effectiveness against hospitalized, lab-confirmed influenza often requires coordinated partnerships among public health agencies, healthcare systems, academic researchers, and laboratories with the capacity to test specimens and manage surveillance-quality data.

Overall, the opportunity supports the infrastructure and coordinated activities needed to generate timely, credible annual estimates of influenza vaccine effectiveness against severe, hospitalization-level outcomes, using laboratory confirmation as a key quality benchmark. The results produced through this kind of platform are intended to inform national understanding of vaccine performance each season and strengthen the evidence base used for vaccination strategies and broader influenza prevention planning.

• The Centers for Disease Control and Prevention - ERA in the health sector is offering a public funding opportunity titled "PPHF 2016: PPHF Epidemiology and Laboratory Capacity Program – US Platform to Measure Influenza Vaccine Effectiveness against Laboratory-confirmed Influenza-associated Hospitalizations – financed in part by 2016 Prevention and Public Heal" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.733.
• This funding opportunity was created on 2016-05-24.
• Applicants must submit their applications by 2016-06-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Others.

Apply for RFA IP 15 00202CONTPPHF16

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: